Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for preventing acute GVHD in allo-HCT
NCT06626737Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dapagliflozin in Acute Graft-Versus-Host Disease (aGvHD), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Cumulative incidence of grade II-IV acute Graft-versus-Host Disease at 100 days. Started Apr 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06626737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06626737.